Sunshine Biopharma Inc

Sunshine Biopharma Inc(SBFM)股票分析

$1.130

+0.010 (+0.89%)收盘时

Loading chart…
High
1.150
Open
1.120
VWAP
1.13
Vol
107.19K
Mkt Cap
8.33M
Low
1.110
Amount
121.12K
EV/EBITDA, TTM
1.15

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

AI analysis of Sunshine Biopharma Inc (SBFM)

buy

Sunshine Biopharma Inc (SBFM) appears to be a good buy right now due to its recent surge in stock price by 66% following drug approval and a reverse stock split, indicating strong market optimism. The current price is $1.15, and despite a year-to-date decline of 91.02%, the projected final change based on historical patterns suggests a potential upside of 121.43%. However, the main risk is the negative earnings per share (EPS) of -1.15 reported in the last earnings, which reflects ongoing financial challenges.

估值指标

The current forward P/E ratio for Sunshine Biopharma Inc (SBFM) is 0.00, compared to its 5-year average forward P/E of -1.84.

Forward P/E

Fair
5Y Average P/E
-1.84
Current P/E
0.00
高估
0.55
低估
-4.24

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
0.05
Current EV/EBITDA
1.15
高估
0.30
低估
-0.20

Forward P/S

Fair
5Y Average P/S
0.16
Current P/S
0.10
高估
0.39
低估
-0.07

Alphio AI Price Scenarios for SBFM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SBFM

$1.99

情景价格

B

Base

Base · 50%SBFM

$1.88

情景价格

B

Bear

Bear · 25%SBFM

$1.86

情景价格

Whales holding SBFM

L

L1 Capital Pty. Limited

+ HoldingSBFM

-0.11%

3M Return

事件时间线

2026-08-31 (ET)

09:30:00

Sunshine Biopharma Receives Approval for Atenolol Tablets

2026-08-28 (ET)

16:30:00

Sunshine Biopharma Files to Sell 24.48M Shares of Common Stock

2026-08-26 (ET)

09:30:00

Sunshine Biopharma Updates on K1.1 Project Progress

2026-08-19 (ET)

09:30:00

Sunshine Biopharma Receives Approval for Generic Enalapril in Canada

2026-08-04 (ET)

09:30:00

Sunshine Biopharma Approves 2mg Generic Dienogest for Canada

资讯

SBFM FAQ — answered by Alphio AI

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sunshine Biopharma Inc (SBFM) appears to be a good buy right now due to its recent surge in stock price by 66% following drug approval and a reverse stock split, indicating strong market optimism. The current price is $1.15, and despite a year-to-date decline of 91.02%, the projected final change based on historical patterns suggests a potential upside of 121.43%. However, the main risk is the negative earnings per share (EPS) of -1.15 reported in the last earnings, which reflects ongoing financial challenges.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始